TY - JOUR AU - Moore, Assaf AU - Kramer, Mordechai R AU - Rosengarten, Dror AU - Shtraichman, Osnat AU - Zer, Alona AU - Dudnik, Elizabeth AU - Korzets, Yasmin AU - Allen, Aaron M PY - 2020/05/31 Y2 - 2024/03/29 TI - Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Primary Lung Cancer in Recipients of Lung Transplant JF - Radiology and Oncology JA - Radiol Oncol VL - 54 IS - 2 SE - Clinical oncology DO - UR - https://radioloncol.com/index.php/ro/article/view/3376 SP - 227-232 AB - <p><strong>Background</strong>: Lung transplantation is a life-saving treatment for patients with end stage lung disease. There may be a higher incidence of lung cancer in lung transplant recipients, and these cancers tend to be diagnosed in a more advanced stage. There is very little data on the safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) for lesions in the native lung in lung-transplant recipients.</p><p><strong>Materials and Methods</strong>: A retrospective chart review of all patients who have undergone lung transplantation and treated with SBRT for lung cancer in the native lung in the Davidoff Cancer Center.</p><p><strong>Results</strong>: Four patients who were treated with SBRT to a total of 5 lesions were included. Two patients were treated without histological confirmation of malignancy. All cases were discussed in a multidisciplinary team before being referred for radiotherapy. Standard SBRT dosing was used. Responses were achieved by imaging in all cases – 3 lesions exhibited a complete response and two lesions partial responses. The patients who had partial responses developed distant metastases and died shortly. No patient developed measurable toxicity.</p><p><strong>Conclusions</strong>: SBRT is effective and safe for the management of lung cancer in lung-transplanted patients. Standard dose and fractionation can be used.</p> ER -